ESC Heart Fail 2021 May 2. Epub 2021 May 2.
Department of Pharmacology, Regional Pharmacovigilance Centre, Pitié-Salpêtrière Hospital, Sorbonne Université, INSERM CIC-1901, AP-HP, Paris, France.
Aims: The major cardiovascular (CV) adverse effects observed with sipuleucel-T from large multi-institutional clinical trials included thromboembolic events, myocardial infarction, and congestive heart failure in up to 0.3% of patients with CV risk factors. The incidence, outcomes, and mechanisms in real-world clinical settings of these CV adverse effects to date have not been fully elucidated. Read More